Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
$1.19
+1.6%
$1.29
$0.85
$4.40
$38.29M0.2531,417 shs45,410 shs
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$14.00
-2.0%
$14.09
$9.83
$17.75
$131.47M0.8117,602 shs9,546 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.43
-3.4%
$12.84
$5.22
$27.38
$156.47M0.43145,571 shs76,404 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1.66
+0.6%
$1.53
$0.77
$2.12
$165.63M2.251.60 million shs2.61 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
+1.64%-7.39%-11.85%+10.19%-63.94%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
-1.96%-2.17%-5.79%+0.36%-7.89%
LifeVantage Co. stock logo
LFVN
LifeVantage
-3.42%-0.72%-1.04%-27.01%+66.40%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
+0.61%+3.11%+9.93%+45.61%+14.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
4.1598 of 5 stars
3.73.00.00.01.93.33.1
LifeVantage Co. stock logo
LFVN
LifeVantage
3.9853 of 5 stars
3.50.01.72.72.91.71.3
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.371 of 5 stars
0.01.00.00.02.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
0.00
N/AN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
3.33
Buy$20.5046.43% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50145.37% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AKTX, LFVN, SLS, and FTLF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/17/2025
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A($0.03) per shareN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$63.86M2.06$0.73 per share19.05$3.04 per share4.61
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.70$0.65 per share19.03$2.38 per share5.22
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M165.63N/AN/A($0.25) per share-6.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
-$10.01MN/A0.00N/AN/AN/AN/A8/18/2025 (Estimated)
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$5.30M$0.8416.5712.73N/A13.38%28.03%15.13%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6922.20N/A3.46%34.29%15.04%8/27/2025 (Estimated)
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)

Latest AKTX, LFVN, SLS, and FTLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$0.24$0.20-$0.04$0.20N/AN/A
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/27/2025Q4 2024
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
$0.22$0.21-$0.01N/AN/AN/A
3/20/2025Q4 2024
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.08+$0.0267-$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.45%N/A26.09%3 Years
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A

Latest AKTX, LFVN, SLS, and FTLF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/A
0.29
0.29
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
0.28
1.50
0.64
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
2.26
2.26

Institutional Ownership

CompanyInstitutional Ownership
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
5.06%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
2.32%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
38.90%
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
61.30%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
932.18 million16.25 millionNot Optionable
FitLife Brands, Inc. stock logo
FTLF
FitLife Brands
209.39 million3.56 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million69.54 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.19 +0.02 (+1.64%)
Closing price 06/13/2025 03:48 PM Eastern
Extended Trading
$1.19 0.00 (0.00%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

FitLife Brands stock logo

FitLife Brands NASDAQ:FTLF

$14.00 -0.28 (-1.96%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$13.88 -0.12 (-0.86%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.43 -0.44 (-3.42%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$13.62 +1.20 (+9.61%)
As of 06/13/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$1.66 +0.01 (+0.61%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.06 (+3.31%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.